Skip to main content

Clinical trial EMR100036-001

A multicenter, Open-label, dose-escalating phase I trial of the DNA-PK inhibitor MSC2490484A in subjects with advanced solid tumors or chronic lymphocytic Leukemia

Organ solid tumors
Trial status Trial closed for recruitment
Trial type
Prospective interventional
Phase Trial phase 1
Academic trial Non
Sponsor MSD - Merck Sharp & Dohme
EudraCT Identifier 2014-003099-22
Last update

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more